# Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

> **NCT04952779** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 750 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Xultophy® (insulin degludec/liraglutide)

## Key facts

- **NCT ID:** NCT04952779
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-02
- **Primary completion:** 2024-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952779, "Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04952779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*